Quarters | |||||||||||||||
(in millions, except per share data) | First | Second | Third | Fourth | |||||||||||
Fiscal 2013(1) | |||||||||||||||
Total revenues(2) | $ | 26,019.9 | $ | 26,381.9 | $ | 25,915.6 | $ | 25,781.4 | |||||||
Cost of revenues(2) | 24,057.8 | 24,266.8 | 23,921.4 | 23,720.4 | |||||||||||
Gross profit | 1,962.1 | 2,115.1 | 1,994.2 | 2,061.0 | |||||||||||
Selling, general and administrative | 1,119.0 | 1,110.8 | 1,118.7 | 1,232.2 | |||||||||||
Operating income | 843.1 | 1,004.3 | 875.5 | 828.8 | |||||||||||
Net income from continuing operations | 380.0 | 574.4 | 453.6 | 518.3 | |||||||||||
Net loss from discontinued operations, net of tax | (1.9 | ) | (23.9 | ) | (15.5 | ) | (12.3 | ) | |||||||
Net income | $ | 378.1 | $ | 550.5 | $ | 438.1 | $ | 506.0 | |||||||
Less: Net income attributable to non-controlling interest | 5.1 | 7.5 | 11.4 | 4.1 | |||||||||||
Net income attributable to Express Scripts | 373.0 | 543.0 | 426.7 | 501.9 | |||||||||||
Basic earnings (loss) per share | |||||||||||||||
Continuing operations attributable to Express Scripts | $ | 0.46 | $ | 0.70 | $ | 0.55 | $ | 0.65 | |||||||
Discontinued operations attributable to Express Scripts | — | (0.03 | ) | (0.02 | ) | (0.02 | ) | ||||||||
Net earnings attributable to Express Scripts | 0.46 | 0.67 | 0.53 | 0.63 | |||||||||||
Diluted earnings (loss) per share attributable to Express Scripts | |||||||||||||||
Continuing operations attributable to Express Scripts | $ | 0.45 | $ | 0.68 | $ | 0.54 | $ | 0.64 | |||||||
Discontinued operations attributable to Express Scripts | — | (0.03 | ) | (0.02 | ) | (0.02 | ) | ||||||||
Net earnings attributable to Express Scripts | 0.45 | 0.66 | 0.52 | 0.63 | |||||||||||
Amounts attributable to Express Scripts shareholders: | |||||||||||||||
Income from continuing operations, net of tax | $ | 374.9 | $ | 566.9 | $ | 442.2 | $ | 514.2 | |||||||
Discontinued operations, net of tax | (1.9 | ) | (23.9 | ) | (15.5 | ) | (12.3 | ) | |||||||
Net income attributable to Express Scripts shareholders | $ | 373.0 | $ | 543.0 | $ | 426.7 | $ | 501.9 | |||||||
Quarters | |||||||||||||||
(in millions, except per share data) | First | Second(3) | Third | Fourth | |||||||||||
Fiscal 2012(1) | |||||||||||||||
Total revenues(2) | $ | 12,132.6 | $ | 27,455.0 | $ | 26,761.6 | $ | 27,365.1 | |||||||
Cost of revenues(2) | 11,300.6 | 25,375.7 | 24,658.7 | 25,067.4 | |||||||||||
Gross profit | 832.0 | 2,079.3 | 2,102.9 | 2,297.7 | |||||||||||
Selling, general and administrative | 265.1 | 1,579.9 | 1,282.2 | 1,390.8 | |||||||||||
Operating income | 566.9 | 499.4 | 820.7 | 906.9 | |||||||||||
Net income from continuing operations | 270.2 | 152.2 | 415.9 | 524.1 | |||||||||||
Net income (loss) from discontinued operations, net of tax | — | 0.8 | (20.0 | ) | (13.1 | ) | |||||||||
Net income | $ | 270.2 | $ | 153.0 | $ | 395.9 | $ | 511.0 | |||||||
Less: Net income attributable to non-controlling interest | 2.4 | 3.4 | 4.5 | 6.9 | |||||||||||
Net income attributable to Express Scripts | 267.8 | 149.6 | 391.4 | 504.1 | |||||||||||
Basic earnings (loss) per share | |||||||||||||||
Continuing operations attributable to Express Scripts | $ | 0.55 | $ | 0.18 | $ | 0.51 | $ | 0.63 | |||||||
Discontinued operations attributable to Express Scripts | — | — | (0.02 | ) | (0.02 | ) | |||||||||
Net earnings attributable to Express Scripts | 0.55 | 0.19 | 0.48 | 0.62 | |||||||||||
Diluted earnings (loss) per share attributable to Express Scripts | |||||||||||||||
Continuing operations attributable to Express Scripts | $ | 0.55 | $ | 0.18 | $ | 0.50 | $ | 0.62 | |||||||
Discontinued operations attributable to Express Scripts | — | — | (0.02 | ) | (0.02 | ) | |||||||||
Net earnings attributable to Express Scripts | 0.55 | 0.18 | 0.47 | 0.61 | |||||||||||
Amounts attributable to Express Scripts shareholders: | |||||||||||||||
Income from continuing operations, net of tax | $ | 267.8 | $ | 148.8 | $ | 411.4 | $ | 517.2 | |||||||
Discontinued operations, net of tax | — | 0.8 | (20.0 | ) | (13.1 | ) | |||||||||
Net income attributable to Express Scripts shareholders | $ | 267.8 | $ | 149.6 | $ | 391.4 | $ | 504.1 | |||||||
(1) | Adjusted to reflect the results of our acute infusion therapies line of business as discontinued. |
(2) | Includes retail pharmacy co-payments of $3,674.4 and $1,496.6 for the three months ended March 31, 2013 and 2012, respectively, $3,204.3 and $3,519.1 for the three months ended June 30, 2013 and 2012, respectively, $2,966.5 and $3,348.9 for the three months ended September 30, 2013 and 2012, respectively, and $2,775.1 and $3,304.0 for the three months ended December 31, 2013 and 2012, respectively. |
(3) | Includes the April 2, 2012 acquisition of Medco. |